Biology:GRAd-COV2
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | viral |
| Clinical data | |
| Routes of administration | Intramuscular |
GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases.[1][2] It is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein.[1] More specifically, the vector used is the simian group C adenovirus GRAd32, isolated from a captive gorilla, with a genome deleted of the entire E1 and E3 regions and the native E4 region replaced with the E4 orf6 of human adenovirus 5 (hAd5).[3]
References
- ↑ 1.0 1.1 GRAd-COV2 Vaccine Against COVID-19. United States National Library of Medicine. 7 January 2021. NCT04528641. https://clinicaltrials.gov/ct2/show/NCT04528641.
- ↑ "ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18–55 Years". ReiThera Srl (Yahoo! Finance). 24 November 2020. https://finance.yahoo.com/news/reithera-announces-grad-cov2-covid-080000811.html.
- ↑ "Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19". Molecular Therapy 29 (8): 2412–2423. April 2021. doi:10.1016/j.ymthe.2021.04.022. PMID 33895322.
External links
 |  |
